NEW YORK (GenomeWeb) – A group of Italian researchers have validated a microRNA-based blood test for early detection of lung cancer that they hope to introduce as a first-line tool that doctors can use to select which patients should go on to receive additional screening with low-dose computed tomography (LDCT).

The so-called miR-Test analyzes patients' serum based on a 13-miRNA signature and deems them either positive or negative for lung cancer. miRNAs are frequently abnormally expressed in tumors, and this irregularity shows up in miRNA profiles in serum and plasma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.